Is letrozole during ovarian stimulation useful in breast cancer patients undergoing fertility preservation to reduce early luteal progesterone levels following GnRH-agonist trigger?

Imane Lalami¹, Julie Labrosse¹, Isabelle Cedrin-Durnerin¹, Marjorie Comtet¹, Claire Vinolas¹, Fabien Krief¹, Christophe Sifer², Maeliss Peigne¹,³ and Michael Grynberg¹,4,5,6*

Abstract

Background: In absence of contraindication, breast cancer patients of reproductive age can undergo fertility preservation with controlled ovarian stimulation for oocyte/embryo cryopreservation before the administration of potentially gonadotoxic treatments. High hormonal levels induced by ovarian stimulation might have an adverse impact on hormone-positive breast cancer. Whether letrozole supplementation during ovarian stimulation (COSTLES) reduces serum progesterone levels after GnRHa trigger remains unknown. We aimed to determine whether COSTLES might be useful for breast cancer patients undergoing fertility preservation to reduce early luteal progesterone levels following GnRH-agonist (GnRHa) trigger.

Methods: All women who underwent COS with GnRH antagonist protocol with GnRHa trigger were included. Serum progesterone level measured 12 h after GnRHa trigger was compared between patients undergoing COS with letrozole supplementation (COSTLES group) and patients undergoing COS without letrozole (Control group) for fertility preservation purposes.

Results: A total of 246 patients were included, of which 84 patients (34.1%) in the COSTLES group and 162 patients (65.6%) in the Control group. All patients in the COSTLES group were BC patients (n = 84, 100%), while the Control group included 77 BC patients (47.5%). Patients in the two groups were comparable. The mean number of oocytes recovered and vitrified at metaphase 2 stage did not significantly differ between the two groups. Serum progesterone levels on the day after GnRHa trigger were significantly lower in the COSTLES group (8.6 ± 0.7 vs. 10.5 ± 0.5 ng/mL, respectively, p < 0.03), as well as serum E2 levels (650.3 ± 57.7 vs. 2451.40 ± 144.0 pg/mL, respectively, p < 0.01). However, the GnRHa-induced LH surge was significantly higher in the COSTLES group (71.9 ± 4.6 vs. 51.2 ± 2.6 UI/L, respectively, p < 0.01).

Conclusions: Our results show that COSTLES for fertility preservation in breast cancer patients using GnRHa trigger reduces serum progesterone levels compared to ovarian stimulation without letrozole. These findings encourage the use of COSTLES in this context to decrease the potential deleterious effect of elevated hormonal levels on hormone-positive breast cancer.

*Correspondence: michael.grynberg@aphp.fr

¹ Department of Reproductive Medicine and Fertility Preservation, Hôpital Jean Verdier, Avenue du 14 Juillet, 93140 Bondy, France

Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
The aim of the present study was to determine whether COSTLES reduces early luteal progesterone levels following GnRHa trigger in BC patients undergoing fertility preservation.

**Methods**

**Patients**

All women undergoing COS for fertility preservation using an antagonist protocol with GnRHa trigger between July 2014 and December 2019 at University Hospital Jean Verdier (France) were included in this retrospective analysis. Patients who had received additional letrozole during the procedure were included in the COSTLES group, while patients who had not received letrozole were included in the Control group. Patients aged below 18 years old or above 42 years old, those who had undergone another type of fertility preservation, cases of metastatic disease and absence of patient consent available were excluded. The study was approved by the institutional review board (CLEA 2021–189) and led according to ethical rules regarding research on patients. For all BC patients, oncologic approval to perform ovarian stimulation for fertility preservation purposes was obtained.

**Ovarian stimulation protocol**

In both groups, ovarian stimulation was performed using a GnRH antagonist protocol and administration of recombinant follicle-stimulating hormone (recFSH) (Follitropin alpha; Gonad-F1, Merck-Serono Pharmaceuticals, France). Exogenous FSH therapy was initiated at a dose ranging from 150 to 450 IU/day, S.C, determined according to the age of the patient, body mass index (BMI), serum anti-Müllerian hormone (AMH) levels and antral follicle count (AFC). For BC patients, fertility preservation was initiated either before or after surgery, prior to systemic treatments. Random-start protocols were specifically performed according to the phase of the menstrual cycle. Follicular phase was defined by serum progesterone levels < 1.0 ng/mL and absence of antral follicle > 12 mm in diameter on ultrasound scan. In these situations, recFSH was administered for at least 5 days at initial dosage. From the Day 6 of recFSH therapy onwards, daily recFSH doses were adjusted according to serum E2 levels and/or the number of growing follicles. GnRH antagonist (Ganirelix, Orgalutran1 0.25 mg, S.C, MSD Pharmaceuticals, France) was initiated to prevent a premature LH surge, at Day 6 of gonadotropin stimulation in most cases. Luteal phase was defined by serum
progesterone levels >3.0 ng/mL. For these patients, recFSH was administered in combination with GnRH antagonists for 5 days and further adjusted according to E2 and/or the number of growing follicles.

In the COSTLES group, administration of letrozole (Femara, Novartis Pharma, 5 mg/day orally) was started on the same day as recFSH and stopped on the day of GnRHa trigger. In all patients, GnRHa alone (triptorelin 0.1 mg, Decapeptyl, Ipsen Pharmaceuticals, 0.2 mg, S.C.) was used for final oocyte maturation and ovulation trigger. Ovulation was triggered when at least 3 preovulatory follicles (16–22 mm in diameter, mean of two orthogonal diameters) were observed on ultrasound scan. As previously described by our team, ovulation trigger was performed on follicles 2–3 mm larger in COSTLES cycles compared to non-COSTLES cycles [13, 22]. Vaginal ultrasound-guided oocyte retrieval was performed 36 h after ovulation trigger using local anaesthesia and/or sedation. In accordance with patient desire and medical advice, oocyte and/or embryo (Day 2, Day 3 or Day 5) cryopreservation was performed.

Ultrasound scans and hormonal measurements

Ovarian reserve and cycle phase were assessed for each patient by ultrasound scan (AFC) and a blood sample measuring serum AMH and progesterone levels. Once COS was started, each patient underwent regular monitoring by ovarian ultrasound scan and blood samples until the day of ovulation trigger by GnRHa. Serum progesterone, LH and E2 levels were measured 12 h after ovulation trigger by GnRHa. Hormonal measurements were performed using commercially available chemiluminescence immunoassays with an automated Eclatys immunoanalyzer (ECLIA, Roche Diagnostics, Meylan, France). The sensitivity of the assay was 5 pg/mL for E2, 0.03 ng/mL for progesterone, and 0.07 IU/L for LH. Intra- and inter-assay coefficients of variation were, respectively, 5 and 10% for E2, 3% and 5% for progesterone, and 2.3% and 2.6% for LH. Ovarian ultrasound scans were performed using a 5.0–9.0 MHz multi-frequency transvaginal probe (Voluson 730 Expert1, General Electric Medical Systems, Paris, France).

Statistical analysis

The primary endpoint was the progesterone level the morning after GnRHa trigger. Secondary endpoints were: serum LH levels following GnRHa trigger; serum E2 levels following GnRHa trigger; progesterone, LH and E2 levels according to the stimulation start phase (follicular phase/luteal phase); and number of mature oocytes.

Data were expressed in terms of frequencies and percentages or by mean values ± standard deviations (SD). Depending on their distribution, Student or Mann–Whitney tests were used to analyze continuous variables. Statistical analysis was performed using XLSTAT 2019 (Addinsoft, Paris, France) on Microsoft Windows 10. P-value < 0.05 was considered statistically significant.

Results

Patient and cycle characteristics

A total of 246 patients were included in the analysis, of which 84 patients (34.1%) in the COSTLES group and 162 patients (65.6%) in the Control group (Fig. 1). All patients in the COSTLES group were BC patients (n=84, 100%). In the Control group, 77 patients were BC patients (47.5%). Indications of FP for the other patients of the Control group are detailed Table 1.

Among BC patients, 122 (75.8%) tumors were positive for estrogen and/or progesterone receptors, while 39 (24.2%) triple negative BC. The majority of BC (97.5%) was classified T1 or T2 according to TNM classification. Distribution was similar between both groups (Table 2).

In the Control group, a majority of patients (n=62/162) had undergone fertility preservation in a cancer context other than BC (blood cell, gastrointestinal, nervous system or cervical cancer, or ovarian borderline tumors), while a minority were cases of fertility preservation for endometriosis (n=9/162) or another benign gynecologic pathology (n=14/162).

Patients in the COSTLES group and Control group were comparable in terms of age, BMI, AMH levels, AFC and COS characteristics (duration of stimulation, total dose of gonadotropins). The mean number of oocytes recovered (14.2 ± 0.7 vs. 14.1 ± 0.9 oocytes, respectively) and vitrified at metaphase 2 stage (10.1 ± 0.6 vs. 10.0 ± 0.7 oocytes) did not significantly differ between the two groups (Table 3).

Outcomes

Serum progesterone levels were significantly lower in the COSTLES group the morning after GnRHa trigger compared to the Control group (8.6 ± 0.7 vs. 10.5 ± 0.5 ng/mL, respectively, p < 0.03). As expected, the morning after GnRHa trigger, serum E2 levels were also significantly lower in the COSTLES group (650.3 ± 57.7 vs. 2451.4 ± 144.0 pg/mL, respectively, p < 0.01). However, the GnRHa-induced LH surge was significantly higher in the COSTLES group compared to the Control group (71.9 ± 4.6 vs. 51.2 ± 2.6 IU/L, respectively, p < 0.01) (Fig. 2).

When analyzing hormonal levels according to the stimulation starting phase, serum progesterone levels after GnRHa trigger did not significantly differ in the COSTLES group whether COS had been started in the follicular or luteal phases (8.5 ± 0.8 vs. 8.3 ± 1.3,
respectively, \( p = 0.9 \) but was significantly higher when COS had been started in the luteal phase in the Control group (13.6 ± 0.6 vs. 9.7 ± 1.3 respectively, \( p = 0.005 \)). Serum E2 levels were significantly higher when COS had been started in the follicular phase in the COSTLES group (752 ± 71.3 vs. 351 ± 44.5 pg/mL, \( p = 0.003 \)) and did not differ in the Control group. No significant difference was observed concerning LH levels according to the stimulation starting phase in the COSTLES group nor the Control group (Fig. 3).

**Discussion**

Our analysis shows that, in patients undergoing COS with GnRHa trigger in a fertility preservation context, COS with letrozole supplementation (COSTLES) is
Fig. 2 Progesterone, LH and E2 levels measured 12 h after trigger in the COSTLES group and control group. Boxplots represent the median, 25th and 75th percentiles.

![Boxplots of progesterone, LH, and estradiol levels in COSTLES and control groups.](image1)

- **Progesterone (ng/mL)**
  - COSTLES vs. Control: p < 0.03
- **LH (ng/mL)**
  - COSTLES vs. Control: p < 0.01
- **Estradiol (pg/mL)**
  - COSTLES vs. Control: p < 0.01

Fig. 3 Progesterone, LH and E2 levels according to ovarian stimulation starting phase (follicular or luteal phase) in the COSTLES and control groups.

![Boxplots of progesterone, LH, and estradiol levels by stimulation phase in COSTLES and control groups.](image2)

- **Follicular phase**:
  - **Progesterone**
    - COSTLES (n=63)
    - Control (n=121)
  - **LH**
    - COSTLES (n=63)
    - Control (n=121)
  - **Estradiol**
    - COSTLES (n=63)
    - Control (n=121)
- **Luteal phase**:
  - **Progesterone**
    - COSTLES (n=21)
    - Control (n=41)
  - **LH**
    - COSTLES (n=21)
    - Control (n=41)
  - **Estradiol**
    - COSTLES (n=21)
    - Control (n=41)
associated to significantly lower progesterone levels the day after GnRHa trigger compared to COS with no letrozole. E2 levels were also significantly lower in case of letrozole administration compared to without.

To our knowledge, our study is the first to report data on progesterone levels in COSTLES and GnRHa trigger in a large cohort. A previous retrospective observational study reporting 3 cases of fertility preservation patients suggested that progesterone levels were higher after ovarian stimulation with letrozole in the middle luteal phase [21], but in one case, recombinant hCG had been used to trigger ovulation. Moreover, a long GnRHa following trigger (24 to 48 h) had been administered, which may have induced a “flare-up” effect by stimulating progesterone production by the corpus luteum. A prospective observational study of 42 patients assessing progesterone levels on the day of hCG trigger, the day of oocyte retrieval, and 3 and 8 days after oocyte retrieval reported that progesterone levels were similar at all times between letrozole-associated COS and COS without letrozole administration [20]. However, contrarily to our study, all patients had been triggered with recombinant hCG. Altogether, data on progesterone levels in this specific context are scarce and studies so far were performed on small effective. Furthermore, despite the fact that GnRHa trigger is the most used and recommended in clinical practice in this context, studies so far were based on patients who had received hCG trigger and/or supplementary treatments during or after stimulation which could induce bias.

Lower progesterone levels after GnRHa trigger compared to hCG trigger may be explained by the fact that the use of GnRHa trigger removes the GnRH antagonist from the GnRH receptor and induces a release of endogenous LH and FSH. LH has a shorter half-life than exogenous hCG, thus resulting in a lower luteotrophic stimulation with faster luteolysis and lower serum progesterone levels [23, 24]. In COSTLES, lower progesterone levels might be further explained by an increase in progesterone metabolism due to the endogenous inhibition of E2 synthesis. Indeed, letrozole inhibits aromatase that converts androgens into E2, resulting in a decrease in E2 synthesis. In ovarian steroidogenesis, E2 inhibits two enzymes of cytochrome P450 C17 17 α-hydroxylase and 17,20 lyase that metabolizes progesterone in androgen [25]. Hence, lower E2 levels may induce a lower inhibition of these two enzymes, resulting in lower progesterone levels [25]. As such, patients with aromatase deficiency have signs of hyperandrogenism [26]. Finally, the higher LH surge in case of letrozole supplementation might stimulate the progesterone metabolism into androgens by its action on cytochrome P450 C17. Indeed, LH could inhibit TGF beta which is a powerful inhibitor of the P450 C17 enzyme that metabolizes progesterone in androgen [27–29].

As expected, E2 levels one day after GnRHa trigger were significantly lower in the COSTLES group. Thus, the higher LH surge following GnRHa administration in the COSTLES group may be associated to a weaker negative feed-back of E2 on the hypothalamic-pituitary axis. The mean number of oocytes recovered and vitrified at metaphase 2 stage were similar in both groups, as related by Oktay et al. [13]. In our subgroup analysis of hormone profile according to stimulation starting phase (follicular or luteal), progesterone was significantly higher in case of luteal phase stimulation start in the Control group, with no difference in LH levels. These results are consistent with previous studies observing a correlation between progesterone levels at the end of the follicular phase and levels of progesterone after trigger by GnRHa [30]. E2 levels are similar with results of Pereira et al. [31] comparing standard stimulations and random start, in which E2 levels after triggering were similar regardless of the early stage of the stimulation phase (1781 versus 1784 pg/mL). In the COSTLES group, progesterone and LH levels were not significantly different depending on the stimulation start phase. Nevertheless, the E2 levels were significantly different with higher levels when COS was started in the follicular phase.

So far, safety data using COSTLES in BC patients are reassuring. Indeed, a prospective controlled study including 337 BC patients, of which 120 had COSTLES for FP prior to chemotherapy, reported no increased risk of recurrence after a mean follow-up of 5.0 years in case of COSTLES compared to BC patients in which no FP had been performed [32]. Similarly, Azim et al.’s analysis of 215 BC patients, of which 79 had COSTLES, suggested that COSTLES did not adversely affect the risk of recurrence nor survival outcomes compared to controls after a median follow-up of 23.4 months [33]. Furthermore, the use of a GnRHa trigger in COSTLES cycles appears to have other advantages, as it was shown to significantly reduce the risk of ovarian hyperstimulation syndrome (OHSS) compared to hCG trigger in 129 BC patients undergoing COS for FP purposes (p = 0.032) [34]. Consistently, Oktay et al. reported that the incidence rate of OHSS was lower in COSTLES cycles of BC patients triggered by GnRHa compared to hCG [35]. In all, although there is no clinical evidence suggesting that the brief elevation of progesterone levels after hCG trigger impairs the survival of BC patients, it seems that the use of GnRHa trigger should be used in COSTLES cycles given its advantages and the reassuring safety data available so far.

Some limitations should be considered when interpreting results of our study. Progesterone levels were
only assessed once, the morning after GnRHa trigger. Hence, our results show that progesterone levels are lower on the day after GnRHa trigger but do not contribute to whether progesterone levels remain consistently lower afterwards. Hence, further studies with several monitoring of progesterone levels would be of interest to confirm our results. Nevertheless, progesterone synthesis is known to increase in the early phase after triggering. Moreover, according to the study by Vuong et al. [36], progesterone levels assessed 12 h after recombinant hCG are correlated with progesterone in the mid-luteal phase. Thus, we can assume that progesterone levels in our study might be extrapolated to progesterone levels during the following days in mid-luteal phase. Larger effectives are also required to confirm results of our analysis on hormonal levels depending on the phase during which COS was started.

Conclusions
Along together, as progesterone levels may have an adverse impact on hormone-sensitive diseases such as BC, our study suggests that progesterone levels after COS are significantly lower on the day after GnRHa trigger when concomitant letrozole is administered compared to traditional COS with no letrozole. These findings are of particular importance for patients undergoing fertility preservation in this context in order to maximize the chances of fertility preservation success while preventing a potential deleterious effect on the disease. Further studies are warranted to confirm our results and understand their underlying mechanisms.

Abbreviations
BC: Breast cancer; COS: Controlled ovarian stimulation; IVM: In vitro maturation; GnRHa: Gonadotropin releasing hormone agonist-antagonists; E2: Oestradiol; RANKL: Nuclear factor kappa-B ligand; COSTLES: Controlled ovarian stimulation with letrozole supplementation; RecFSH: Recombinant follicle-stimulating hormone; BMI: Body mass index; AMH: Anti-Müllerian hormone; AFC: Antral follicle count.

Acknowledgements
None

Author’s contributions
Wrote the paper: IL, JL, MG. Proofread English text: JL. Conceived and designed the study: MC, CS, ICD, MP, MG. Analyzed the data: ICD. Contributed to materials/analysis tools: FK, CV, MP. All authors read and approved the final manuscript.

Funding
The authors have no funding source to declare.

Availability of data and materials
All data generated or analysed during this study are included in this published article.

Declarations
Ethics approval and consent to participate
The study was approved by the institutional review board (CLEA 2021–189) and conducted according to ethical rules regarding research on patients. For all breast cancer patients, oncologic approval to perform ovarian stimulation for fertility preservation purposes was obtained.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1. Department of Reproductive Medicine and Fertility Preservation, Hôpital Jean Verdier, Avenue du 14 Juillet, 93140 Bondy, France. 2. Department of Cyto genetic and Reproductive Biology, Hôpital Jean Verdier, Avenue du 14 Juillet, 93140 Bondy, France. 3. University Sorbonne Paris Nord, Paris 13, 93022 Bobigny, France. 4. Department of Reproductive Medicine and Fertility Preservation, Hôpital Antoine Béclère, 157, rue de la Porte de Trivaux, 92140 Clamart, France. 5. University Paris-Sud, Université Paris Saclay, 94276 Le Kremlin Bicêtre, France. 6. Unity Inserm U1133, University Paris-Diderot, 75013 Paris, France.

Received: 12 March 2022 Accepted: 26 May 2022
Published online: 11 June 2022

References
1. Desantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA Cancer J Clin. 2011;61(6):409–18.
2. Partridge AH, Gelber S, Peppercorn J, Ginsburg E, Sampson E, Rosenberg R, et al. Fertility and Menopausal Outcomes in Young Breast Cancer Survivors. Clin Breast Cancer. 2008;8(1):65–9.
3. INCA - Les cancers en France [Internet]. [cited 2021 Jan 17]. Available from: https://www.e-cancer.fr/resources/cancers_en_france/?page=64
4. Breast cancer survival statistics [Internet]. Cancer Research UK. 2015 [cited 2021 Jan 23]. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer/survival
5. Lambertini M, Peccatori FA, Demeestere I, Amant F, Wyns C, Stukenborg J-B, et al. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guideline. Ann Oncol. 2020;31(12):1664–78.
6. Morgan S, Anderson RA, Gourley C, Wallace WH, Spears N. How do chemotherapeutic agents damage the ovary? Hum Reprod Update. 2012;18(5):525–35.
7. Martinez F, International Society for Fertility Preservation–ESHRE–ASRM Expert Working Group. Update on fertility preservation from the Barcelona International Society for Fertility Preservation–ESHRE–ASRM 2015 expert meeting: indications, results and future perspectives. Fertil Steril. 2017;108(3):407–415.e11.
8. Mauri D, Gazouli I, Zarkavelis G, Papadaki A, Movreoidis L, Gkoura S, et al. Chemotherapy Associated Ovarian Failure. Front Endocrinol [Internet]. 2020 [cited 2021 Jan 23];11. Available from: https://www.frontiersin.org/articles/https://doi.org/10.3389/fendo.2020.572388/full
9. Grynborg M, Sonigo C, Santulli P. Fertility Preservation in Women. N Engl J Med. 2018;378(4):400.
10. Oktay K, Harvey BE, Partridge AH, Quinn GP, Reinecke J, Taylor HS, et al. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018;36(19):1994–2001.
11. Practice Committee of the American Society for Reproductive Medicine. Electronic address: asrm@asrm.org. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertil Steril. 2019;112(6):1022–33.
12. Cahill DJ, Wardle PG, Harlow CR, Hunt LP, Hull MG. Expected contribution to serum oestradiol from individual ovarian follicles in unstimulated cycles. Hum Reprod. 2000;15(9):1909–12.
13. Oktay K, Houvitz A, Sahin G, Oktem O, Safo B, Cil A, et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab. 2006;91(10):3885–90.

14. Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol. 2008;26(16):2630–5.

15. Axlund SD, Sartorius CA. Progesterone regulation of stem and progenitor cells in normal and malignant breast. Mol Cell Endocrinol. 2012;357(1–2):71–9.

16. Asselin-Labat M-L, Shackleton M, String J, Vaillant F, Forrest NC, Eaves CJ, et al. Steroid hormone receptor status of mouse mammary stem cells. J Natl Cancer Inst. 2006;98(14):1011–4.

17. Kim JJ, Kunta T, Bulun SE. Progesterone Action in Endometrial Cancer, Endometriosis, Uterine Fibroids, and Breast Cancer. Endocr Rev. 2013;34(1):130–62.

18. Josh P, Jackson HW, Berstein AG, Di Grappa MA, Mote PA, Clarke CL, et al. Progesterone induces adult mammary stem cell expansion. Nature. 2010;465(7299):803–7.

19. Mansor JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, et al. The Women's Health Initiative Hormone Therapy Trials: Update and Overview of Health Outcomes During the Intervention and Post-Stopping Phases. JAMA. 2013;310(13):1353–68.

20. Goldrat O, Gervy C, Englert Y, Delbœuf A, Demeestere J. Progesterone levels in letrozole associated controlled ovarian stimulation for fertility preservation in breast cancer patients. Hum Reprod. 2015;30(9):2184–9.

21. Alivaggi C, Marci R, Vallone R, Conforti A, Di Rella F, Strina I, et al. High progesterone levels during the luteal phase related to the use of an aromatase inhibitor in breast cancer patients. Eur Rev Med Pharmacol Sci. 2017;21(13):3134–8.

22. Sonigo C, Sermondade N, Calvo J, Benard J, Sifer C, Grynberg M. Impact of letrozole supplementation during ovarian stimulation for fertility preservation in breast cancer patients. Eur J Obstet Gynecol Reprod Biol. 2019;14:100049.

23. Engelmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril. 2008;89(1):84–91.

24. Beckers NGM, Macklon NS, Eijkemans MJ, Ludwig M, Felberbaum RE, Diedrich K, et al. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. J Clin Endocrinol Metab. 2003;88(9):4186–92.

25. Taniguchi F, Couse JF, Rodriguez KF, Emmen JMA, Poinder D, Korach KS. Estrogen receptor-alpha mediates an intraovarian negative feedback loop on thecaal cell steroidogenesis via modulation of Cyp17a1 (cytochrome P450, steroid 17alpha-hydroxylase/17,20 lyase) expression. FASEB J. 2007;21(2):586–95.

26. Ludwikowski B, Heger S, Datz N, Richter-Unruh A, Gonzalez R. Aromatase deficiency: rare cause of virilization. Eur J Pediatr Surg. 2013;23(5):418–22.

27. Smitz J, Andersen AN, Devroede P, Aro J-C, MERIT Group. Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinant FSH in IVF patients. Hum Reprod. 2007;22(3):676–87.

28. Cheifetz S, Hernandez L, Lahlo M, ten Dijke P, Ivata KK, Massagué J. Distinct transforming growth factor-beta (TGF-beta) receptor subsets as determinants of cellular responsiveness to three TGF-beta isoforms. J Biol Chem. 1990;265(33):20533–8.

29. Fournet N, Weitsman SR, Zachow RJ, Magoffin DA. Transforming growth factor-beta inhibits ovarian 17 alpha-hydroxylase activity by a direct noncompetitive mechanism. Endocrinology. 1996;137(1):166–74.

30. Cakmak H, Katz A, Cedars MI, Rosen MP. Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. Fertil Steril. 2013;100(6):1673–80.

31. Pereira N, Voskullen-Gonzalez A, Hancock K, Lekovich JP, Schattman GL, Rosenwaks Z. Random-start ovarian stimulation in women desiring elective cryopreservation of oocytes. Reprod Biomed Online. 2017;35(4):400–6.

32. Kim J, Turan V, Oktay K. Long-Term Safety of Letrozole and Gonadotropin Stimulation for Fertility Preservation in Women With Breast Cancer. J Clin Endocrinol Metab. 2016;101(4):1364–71.

33. Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol. 2008;26(16):2630–5.

34. Reddy J, Turan V, Bedoschi G, Moy F, Oktay K. Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience. J Assist Reprod Genet. 2014;31(7):927–32.

35. Oktay K, Türkçüoğlu I, Rodriguez-Wallberg KA. GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation. Reprod Biomed Online. 2010;20(6):783–8.

36. Vuong LN, Ho TM, Pham TD, Ho VNA, Andersen CY, Humaidan P. The early luteal hormonal profile in IVF patients triggered with hCG. Hum Reprod. 2020;35(1):157–66.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.